Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype

Francis Mastaglia, M. Needham, A. Scott, I. James, P. Zilko, T. Day, L. Kiers, A. Corbett, Campbell Witt, Richard Allcock, Nigel Laing, M. Garlepp, Frank Christiansen

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Susceptibility to sIBM is strongly associated with the HLA-DRB1*03 allele and the 8.1 MHC ancestral haplotype (HLA-A1, B8, DRB1*03) but little is known about the effects of allelic interactions at the DRB1 locus or disease-modifying effects of HLA alleles. HLA-A, B and DRB1 genotyping was performed in 80 Australian sIBM cases and the frequencies of different alleles and allele combinations were compared with those in a group of 190 healthy controls. Genotype–phenotype correlations were also investigated. Amongst carriers of the HLA-DRB1*03 allele, DRB1*03/*01 heterozygotes were over-represented in the sIBM group (p <0.003) while. DRB1*03/*04 heterozygotes were under-represented (p <0.008). The mean age-at-onset (AAO) was 6.5 years earlier in DRB1*03/*01 heterozygotes who also had more severe quadriceps muscle weakness than the rest of the cohort. The findings indicate that interactions between the HLA-DRB1*03 allele and other alleles at the DRB1 locus can influence disease susceptibility and the clinical phenotype in sIBM.
Original languageEnglish
Pages (from-to)763-765
JournalNeuromuscular Disorders
Volume19
Issue number11
DOIs
Publication statusPublished - 2009

Fingerprint Dive into the research topics of 'Sporadic inclusion body myositis: HLA-DRB1 allele interactions influence disease risk and clinical phenotype'. Together they form a unique fingerprint.

Cite this